LAG3 and renal cell carcinoma: In RCC, phase-Ib/II trials are testing anti-LAG3 Favezelimab, anti-ILT-4 MK-4830, and anti-TIGIT Vibostolimab with Pembrolizumab for advanced ccRCC (236, 237).